Treatment of cancer using a combination of an antibody that binds to EGFR and a cytotoxic drug

A combination therapy using an EGFR-binding antibody with fluoropyrimidines and platinum-based agents addresses CRC resistance by enhancing treatment efficacy, particularly for metastatic CRC, targeting EGFR and LGR5, offering improved outcomes for adenocarcinomas and squamous cell carcinomas.

JP2026500788APending Publication Date: 2026-01-08MERJUS
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2025538500
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-12-28
Filing Date
2023-12-28
Publication Date
2026-01-08

AI Technical Summary

Technical Problem

Colorectal cancer (CRC) has developed resistance to current treatments, leading to limited therapeutic options, particularly for metastatic CRC, with anti-EGFR therapy resistance due to mutations or innate resistance, necessitating new therapies to improve treatment efficacy.

Method used

A combination therapy using an antibody that binds to EGFR, in conjunction with fluoropyrimidines, platinum-based chemotherapeutic agents, BCL-2 inhibitors, or SN-38, to enhance treatment effectiveness for CRC, including adenocarcinomas and squamous cell carcinomas, by targeting EGFR and optionally LGR5.

Benefits of technology

The combination therapy demonstrates enhanced efficacy compared to individual agents, providing effective treatment options for CRC, including metastatic CRC, especially in RAS and RAF wild-type cases, by targeting EGFR and LGR5, even after resistance to standard therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026500788000009
    Figure 2026500788000009
  • Figure 2026500788000010
    Figure 2026500788000010
  • Figure 2026500788000011
    Figure 2026500788000011
Patent Text Reader

Abstract

The present disclosure relates to the field of therapeutic antibodies for treating subjects with cancer. More specifically, the present disclosure relates to treating cancer using an antibody comprising a variable domain that binds to the extracellular portion of EGFR, or a functional portion, derivative, and / or analog thereof, in a combination therapy further comprising administering a fluoropyrimidine, a platinum-based chemotherapeutic agent, a BCL-2 inhibitor, or SN-38. The cancer may be head and neck cancer, gastric cancer, esophageal cancer, gastroesophageal junction cancer, non-small cell lung cancer, or colorectal cancer. The present disclosure also relates to pharmaceutical formulations, kits of parts, and dosage regimens.
Need to check novelty before this filing date? Find Prior Art